Sionna Q3 net loss $20.3M; starts Phase 2a trial for SION-719; cash runway into 2028

Sionna Therapeutics, Inc.

2025-Q3 EPS reported -$1.43 vs consensus -$0.49 ▼ miss (-189.5%)

Net loss of $20.3M in Q3 2025 versus $25.4M in Q3 2024; R&D expenses fell to $16.0M from $24.6M due to prior year license charge.
Cash and equivalents totaled $325.0M as of Sep 30, 2025, expected to fund operations into 2028.
Initiated PreciSION CF Phase 2a proof-of-concept trial for SION-719 as add-on to standard of care in cystic fibrosis; topline data expected in mid-2026.
Initiated Phase 1 trial evaluating SION-451 in proprietary dual combinations with CFTR correctors SION-2222 and SION-109; topline data mid-2026.
Appointed Caroline Stark Beer as Chief Business Officer in September 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.